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Abstract
The purpose of the present study is to explore the progression of type 1 diabetes (T1D) in Danish children 12 months after
diagnosis using Latent Factor Modelling. We include three data blocks of dynamic paraclinical biomarkers, baseline clinical
characteristics and genetic profiles of diabetes related SNPs in the analyses. This method identified a model explaining
21.6% of the total variation in the data set. The model consists of two components: (1) A pattern of declining residual b-cell
function positively associated with young age, presence of diabetic ketoacidosis and long duration of disease symptoms
(P= 0.0004), and with risk alleles of WFS1, CDKN2A/2B and RNLS (P= 0.006). (2) A second pattern of high ZnT8 autoantibody
levels and low postprandial glucagon levels associated with risk alleles of IFIH1, TCF2, TAF5L, IL2RA and PTPN2 and protective
alleles of ERBB3 gene (P= 0.0005). These results demonstrate that Latent Factor Modelling can identify associating patterns in
clinical prospective data – future functional studies will be needed to clarify the relevance of these patterns.
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Introduction
T1D is the end result of T-cell mediated autoimmune
destruction of the pancreatic b-cells. Several studies have
described the natural history of T1D with respect to b-cell failure
and glycaemic control in order to understand disease progression
[1–3]. In those studies the predominant factors associated with a
rapid loss of residual b-cell function are young age [1,2] and severe
diabetic ketoacidosis (DKA) at diagnosis [2,4]. The causal effect of
autoantibodies on residual b-cell function remain unclear as
conflicting results are reported [2,5]. However, a positive
association between the arginine variant of the ZnT8 autoanti-
bodies (ZnT8Arg) and the residual b-cell function has recently
been reported [6–8]. Genome wide association studies (GWAS)
have identified in excess of 40 regions with significant association
to T1D, but the functionality of these genes in disease mechanisms
is not addressed by GWAS studies. Few of the T1D susceptibility
genes (INS and PTPN22 genes) have so far been associated with
residual b-cell function and glycaemic control during the first year
after diagnosis in newly diagnosed children with T1D [9,10].
Thus, although the residual b-cell function has been extensively
studied, individual variation remains to be explained.
The complexity of T1D pathogenesis advocates for new
modelling methods in biomedical systems of equivalent complexity
[11,12], especially regarding gene-gene interactions (epistasis) [13].
The usage of Latent Factor Modelling for analysis of complex data is
an emerging field originating from genomics, metabolomics and
chemometric sciences and is gaining acceptance in clinical
research [14,15]. By applying the multi-block approach when
analysing closely monitored clinical cohorts instead of classical
regression analyses we may identify new associations between
biomarker patterns related to disease progression, corresponding
baseline characteristics and gene-gene interactions [16].
The aim of this study was to investigate patterns of clinical-,
paraclinical- and genetic characteristics during the first 12 months
after diagnosis in a Danish cohort of 129 children with newly
diagnosed T1D by applying Latent Factor Modelling.
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Materials and Methods
Subjects
The Danish Remission Phase Study is a prospective long-term
observational study conducted in four paediatric departments. A
total of 129 children and adolescents aged less than 17 years with
newly diagnosed T1D were enrolled in the study from April 2004
to August 2006 and followed for 12 months from onset of T1D,
defined as the first insulin injection. The detailed study design has
previously been described by Andersen et al [8]. The study was
performed according to the criteria of the Helsinki II Declaration
and was approved by the Danish National Committee on
Biomedical Research Ethics (Journal number: H-KA-04010-m).
Older patients and all parents or guardians gave written informed
concept. Data were transmitted anonymously by the centers;
patients were identified by center number and patient code.
HbA1c, Insulin Dose Adjusted HbA1c (IDAA1c) and Partial
Remission
HbA1c was measured at disease onset, 1, 3, 6, 9, and 12 months
after diagnosis (61 week). Capillary samples for HbA1c analysis
were centrally measured using Bio-Rad HbA1c sample preparation
kit (Bio-Rad Laboratories, Munich, Germany) as described by
DCCT [1]. Normal range for the assay was 4.4–6.3% (about 0.3%
higher than the DCCT method). Daily insulin dose (U/kg) was
recorded 1, 3, 6, 9 and 12 months after diagnosis. IDAA1c was
calculated as IDAA1C=HbA1c (percent)+[4 x insulin dose (units
per kilogram per 24 h)]. Partial remission was defined as an
IDAA1C #9 as described by Mortensen et al [17].
Residual b-cell Function
After 1, 3, 6 and 12 months of diabetes (61week) a mixed meal
tolerance test (MMTT) was performed to stimulate endogenous C-
peptide and proinsulin release as previously described [8]. The
included children received 6 ml/kg (maximum 360 ml.), accord-
ing to DCCT standards [1], of BOOSTH Original Drink (237 ml
or 8 FL OZ containing 41 g carbohydrate, 10 g protein and 4 g
fat, 240 kcal in all from Novartis Medical Health, Inc., Minne-
apolis, MN, USA (www.boost.com/nutritional-drinks/boost-
original). Serum samples were stored on dry ice at 220 uC until
shipment to Steno Diabetes Centre. Stimulated serum C-
peptide was analysed by a fluoroimmunometric assay as
previously described [2]. Stimulated serum proinsulin was
analysed by a sandwich ELISA assay as described by Kaas et al
[18]. There were 129 patients who contributed with at least one
measurement.
Glucagon, Glucose-dependent Insulinotrophic
Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1)
Glucagon, GIP and GLP-1 were all measured centrally after
extraction of plasma with 70% ethanol (vol/vol, final concentra-
tion) [19]. There were 129 patients who contributed with at least
one measurement.
Autoantibodies
The conventional T1D autoantibodies were measured in serum
samples: Islet Cell autoantibodies (ICAs) by use of immuno-
fluorescence assay [20]; insulin autoantibodies (IAAs), anti-
bodies against Glutamic Acid Decarboxylase (GADAs) and
Insulinoma-associated Antigen-2 (IA-2A) by use of specific
radiobinding assays [21]. The cut-off values for ICA, IAA, GADA
and IA-2A positivity were 2.5 Juvenile Diabetes Foundation units
(JDFU), 2.80 relative units (RU), 5.36 RU and 0.43 RU,
respectively. Zinc transporter 8 autoantibodies (ZnT8Abs)
were measured on serum samples by use of specific radio binding
assays (RBA) for each variant (arginine (ZnT8Arg), tryptophan
(ZnT8Trp) and glutamine (ZnT8Gln)) and the triple mix assay
(ZnT8tripleAb) as described previously [8]. ZnT8Ab positivity was
defined as titer values $ 60 U/ml, 58 U/ml and 65 U/ml and 58
U/ml for ZnT8Arg, ZnT8Trp, ZnT8Gln and ZnT8tripleAb,
respectively. There were 129 patients who contributed with at least
one measurement.
HLA Typing
Time-resolved fluorometry was used for identification of HLA-
DQB1 alleles (02, 0301, 0302, 0304, 0602, 0603, and 0604) as
described in details [22]. The HLA-DQB1 genotyping risk score
was as follows: ’very high risk’ included only DQB1*0302-
DQB1*02 heterozygous individuals, ’high risk’ included
DQB1*0302/*0302, 0302/X, 02/02, and 02/X, ’moderate risk’
included DQB1*0302/0301, 0302/0603, 02/0301, 02/0603, and
XX, and ’low risk’ included DQB1*0302/0602, 02/0602, 0301/
X, 0603/X, where X are all other DQB1 alleles. Patients were
subdivided into three HLA risk groups (very high, high and
moderate/low) according to their HLA-DQB1 genotype [23]. 125
children were HLA genotyped, the genotype distribution was: very
high risk n= 48, high risk n= 55 and moderate/low risk n = 22.
Genotyping
In total 125 children were genotyped for 51 single nucleotide
polymorphisms (SNPs) from different genomic loci chosen from
T1D and T2D GWAS. Genotyping was done using Taqman allele
discrimination (KBioscience, Hoddesdon, UK). The 31 selected
T1D SNPs were: [24]: INS (rs3842753 and rs689), PTPN22
(rs2476601), PTPN2 (rs478582 and rs1893217), IFIH1
(rs1990760), IL2RA (rs11594656), KIAA0350 (rs12708716), SHSB3
(rs3184504), ERBB3 (rs2292239), TAF5L (rs3753886), ICAM1
(rs1799969), SORCS1 (rs1358030), UBASH3A (rs9976767), BACH2
(rs3757247), CTSH (rs3825932), C1QTNF6 (rs229541), IL6
(rs1800795), PDCD1 (rs11568821), BNC2 (rs566369), IL10
(rs3024505), IL7 (rs6897932), TNFAIP3 (rs2327832), SKAP2
(rs7804356), CTRB1/CTRB2 (rs7202877), GSDMB/ORMDL3
(rs2290400), CTLA4 (rs231775 and rs3087243), RNLS
(rs10509540), GLIS3 (rs7020673), PRKCQ (rs11258747). The 20
selected T2D SNPs were: [25]: SLC30A8 (rs13266634), KCNJ11
(rs5215), TCF7L2 (rs7901695 and rs7903146), CDKN2A/2B
(rs564398 and rs10811661), IGFBP2 (rs4402960), CDKAL1
(rs10946398), HHEX/IDE (rs5015480 and rs1111875), WFS1
(rs10010131), ADAMTS9 (rs4607103), PPARG (rs1801282),
THADA (rs7578597), CDC123/CAMK1D (rs12779790), FTO
(rs9939609), JAZF1 (rs864745), NOTCH2 (rs10923931),
TSPAN8/LGR5 (rs7961581) and HNF1B (rs4430796).
Statistical Methods
Conventional statistical methods. Data are descriptively
presented as median and range for non-normally distributed
parameters and mean 6 standard deviation (SD) for normally
distributed parameters. Non-normally distributed parameters were
analysed on logarithmic scale. The analyses were performed using
SAS (version 9.2, SAS Institute; Cary, NC, USA) and R (http://
mirrors.dotsrc.org/cran/).
Latent factor models for analysis of complex data – multi-
block approach. The data are organized as three individual
data blocks schematized generically in Figure 1: Block I:
Paraclinical markers such as number of insulin injections, fasting
blood glucose, stimulated blood glucose (SBG), daily insulin dose
per kg, body mass index (BMI), HbA1c, IDAA1c, insulin
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antibodies, autoantibodies: GADA, ICA, IA-2A, ZnT8Arg,
ZnT8Trp, ZnT8Gln and ZnT8tripleAB and serum level of
stimulated: C-peptide, proinsulin, glucagon, GIP and GLP-1
measured 1, 3, 6 and 12 months after diagnosis. Block II: Clinical
and paraclinical markers registered at onset (baseline): Number of
weeks before diagnosis with polyuria and polydipsia, pubertal
status, blood glucose, standard bicarbonate (HCO3
-), gender, age,
DKA (HCO3
- #15 mmol/L), severe DKA (HCO3
- #5 mmol/L),
HLA risk groups and HbA1c. Block III: T1D and T2D related
genetic polymorphisms as described above.
The aim of the analysis was to extract biologically intuitive
patterns reflected in the different data blocks. We used a multi-
block procedure, Coupled Matrix Tensor Factorization [26,27], to
derive common components/factors. The method is an extension
of the well-known methods for factorization of matrices (Latent
Factor Models), Principal Component Analysis (PCA), and higher order
arrays, PARAallel FACtor analysis (PARAFAC). The large number of
variables in population-based cohorts is significantly prone to
spurious discoveries, for which reason correction for multiple
testing is often applied, e.g. Bonferroni correction. The Latent Factor
Modelling account for multiple testing by reducing the dimension-
ality in a way similar to principal component analysis [28].
In order to simplify the factors a sparsity constraint was imposed
with the result that variables with small contribution are set to
zero. Hereby the individual factors only reflect a subset of the
variables and are therefore easier to interpret. Thus, from the
chosen model based on the three data blocks a number of relevant
components are extracted. Each component describes a certain
pattern of variation and may be reflected in several modes
(biomarkers over time, baseline characteristics and genes).
Therefore, all components are parts of the same model reflecting
different association patterns between the data blocks. Examina-
tion of the biomarker mode reveals which biomarkers are related to
the component, and examination of the time mode reveals how this
pattern progress over time, see Figure 1 ‘Biomarkers’. Here
variable A has a high positive so called loading and B a high
negative loading; this means that these two variables, in this
pattern, are opposite correlated. The inclusion of the timely
development indicates that A increases and B decreases over time.
Further, the pattern is extracted such that profiles in ‘Baseline
characteristics’ and ‘Genes’ are simultaneously estimated. In
figure 1 ‘Genes’, G1 is therefore positively associated- whereas
G2 is negatively associated with this pattern in the biomarker
development. Likewise baseline variable B1 is positively associated
with the pattern (to highlight a few).
Validation. The multi-block model was internal validated by
pattern to pattern association via random permutation testing,
which estimates the significance of the associations between the
data-blocks in the true model.
The multi-block model was validated further by the use of two
different approaches for external validation: i) split half consistency
and ii) replication in an independent cohort. A split half analysis
mitigates the process of estimating the same model in two
independent datasets by splitting the data into two equally sized
portions followed by building of two independent models. These
are compared in terms of pattern estimates by either correlation
coefficients (for baseline and biomarker variables) or selectivity
patterns for genes (by homogeneity testing). Split half analysis is
based on models built on reduced data with a resulting loss of
statistical power. Optimally the results can be reproduced in an
independent cohort. The Hvidoere Remission Phase Cohort
including 275 newly diagnosed children with T1D collected
through 18 paediatric centres in Europe and Japan represent an
independent, but slightly different cohort [2]. The same blood
samples were collected as for the cohort presented in this study (the
Danish Remission Phase Cohort) 1, 6 and 12 months after
diabetes onset. An independent model is built on these data and
compared to the model built on the Danish Remission Phase
Cohort in a similar fashion as for the split half analysis.
For further methodological details see appendix S1.
Results
Demographic and Clinical Characteristics
Data were obtained from 129 patients, 63 girls (mean age
10.2 yrs) and 66 boys (mean age 9.9 yrs), 95% were Caucasian.
Clinical information including anthropometric data, ethnicity,
pubertal status, symptoms prior to diagnosis and metabolic status
(DKA, stimulated blood glucose and HbA1c) are summarized in
Table 1 according to age group.
The median level of stimulated C-peptide was unchanged
from 1 to 3 months, but subsequently decreased from 3 to 12
months after clinical disease onset (Table 2). The association
between age and stimulated C-peptide is shown in Figure 2A for
each individual. Regression analysis revealed an increasing
positive significant effect of age to stimulated C-peptide through-
out the study period (P#0.0001). Mean HbA1c and IDAA1c
declined from disease onset, reached a nadir 3 months after
diagnosis, and increased thereafter continuously throughout the
study period (Table 2). The association between age and HbA1c
and IDAA1c, respectively, is shown in Figure 2B and 2C for each
individual. Only 21.1% of the very young children (,5 years) were
in partial remission (IDAA1c #9) 3 months after diagnosis,
whereas 74.3% and 68.9% of the children in the two oldest age
groups (5–10 years and.10 years) were in partial remission at this
time point (P = 0.0002) (Figure 2C).
Figure 1. Diagram of a single factor/component from a -block
model examining biomarkers over time (Biomarkers) in
relation to baseline characteristics (Baseline) and Genetic
background (Genes). The pattern indicates that e.g. the biomarker
A increases- and the biomarker B decreases over time. This pattern is
e.g. related to high values of the baseline characteristics B1 and high
number of risk alleles for gene G1 and low number of risk alleles for
gene G2.
doi:10.1371/journal.pone.0064632.g001
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Latent Factor Modelling (multi-block analyses)
The three data blocks were modelled by a two component
multi-block model describing 21.6% of the total variation in the
block of dynamic paraclinical biomarkers. These components were
assigned ‘b-cell function’ and ‘ZnT8Ab’. The first component
reflects data from all three data blocks, whereas the second
component only reflects data from the dynamic biomarker- and
gene blocks.
Component 1: Identification of Baseline Clinical
Characteristics and Genetic Profiles Related to Declining
‘b-cell Function’ (dynamic paraclinical biomarker block)
The first association pattern from the multi-block analyses is
shown in Figure 3A. This component describes a dynamic pattern
of biomarkers related to declining b-cell function reflected as a
decline of stimulated C-peptide and proinsulin in combination
with an increase of stimulated blood glucose, glucagon and insulin
dose per kg bodyweight during the first 12 months after onset
(Figure 3A (I)). This component is denoted ‘b-cell function’. The
‘b-cell function’-component is associated with a pattern of baseline
clinical characteristics consisting of young age, DKA, low standard
bicarbonate, high level of blood glucose and duration of symptoms
(polyuria and polydipsia) (Figure 3A (II)). The described associa-
tion between the pattern of dynamic biomarkers and the
corresponding pattern of baseline characteristics of the ‘b-cell
function’-component are significant (P = 0.0004). Furthermore, the
‘b-cell function’-component is associated with a genetic pattern of
multiple number of risk alleles of T1D associated SNPs from the
insulin VNTR region (INS (rs3842753 and rs689) and the RNLS
(rs10509540) together with T2D associated SNPs in WFS1
(rs10010131) and CDKN2A/2B (rs564398) genes and protective
alleles of the T2D associated SNP (rs7961581) in the TSPAN8-
LGR5 gene (P= 0.006) (Figure 3A (III).
Component 2: Identification of Genetic Profiles Related
to the Dynamic ZnT8Ab Profile
The second component, denoted ‘ZnT8Ab’-component, de-
scribes the development of ZnT8Abs (reflected as high levels of
ZnT8Arg, ZnT8Trp, ZnT8Gln and ZnT8TripleAb) combined
with low levels of stimulated glucagon (Figure 3B). This pattern
increases until 6 months after diagnosis, and subsequently
stabilizes (Figure 3B (I)). The ‘ZnT8Ab’-component is strongly
related to a genetic profile of risk alleles of SNPs in the T1D
related genes: TAF5L (rs3753886), HNF1B (rs4430796), IL2RA
(rs11594656) and PTPN2 (rs1893217) in combination with the
T2D associated SNP: CDKAL1 (rs10946398); and protective alleles
of the T1D associated gene ERBB3 (rs2292239) (P = 0.0005)
(Figure 3B (III)). The ‘ZnT8Ab’-component was not found to be
correlated to age or any other of the baseline characteristics
(P.0.5).
External Validation of the Multi-block Model
In the split half analysis the components were compared
between the two strata. Especially the biomarker profiles in
relation to the ‘b-cell function’-component and ‘ZnT8Ab’-
component, were consistent (P = 0.002 and P= 0.0001). The
selection of genes in the split-half procedure were to some extend
inconsistent (P = 0.2) but these analyses were especially hampered
by the loss of modelling power by reducing the data with 50%.
Comparison with a model based on the Hvidoere Cohort (n = 275)
revealed, that the first component (‘b-cell function’) is consistent
(P = 0.009), with a similar baseline pattern (P= 0.0028), including
a fair overlap in genes selected for this component (P = 0.08).
However, the pattern of the second component (‘ZnT8Ab’) was
not strong enough to be revealed by a two component model
based on the Hvidoere Cohort.
Discussion
‘b-cell Function’-component
The present study applies multi-block methodology based on Latent
Factor Modelling (appendix S1) with the aim of identifying
associating clinical, paraclinical and genetic patterns in a well
characterized cohort of children with newly diagnosed T1D. We
suggest applying this modelling method to address one of the
largest challenges in post-GWA studies, the association between
disease-related risk loci and metabolic/clinical phenotypes. The
first component extracted from the model, ‘b-cell function’, reflects
a well-known pattern between stimulated C-peptide, age [1–3]
and metabolic derangements [4]. When applying multi-block analysis
we did, however, identify less well described relations between
clinical observations, as duration of symptoms and decline of b-cell
function, indicating the importance of early diagnosis of the
disease. The cohesion between stimulated C-peptide and proin-
sulin is supported by previous reports [2,18,29]. We refine the
dynamic pattern of declining b-cell function represented by
stimulated C-peptide and proinsulin with the combination of
Table 1. Clinical and demographic data at onset and 1 month (`) after diagnosis by age groups: *P,0.05.
Age ,5 yrs 5$ Age ,10 yrs Age $10 yrs
Number (male/female) 14/5* 14/22 38/36
Mean age (range) (yrs) 3.2 (0.6–4.9) 7.9 (5.2–9.8) 12.8 (10.1–16.6)
Mean BMI (range) (kg/m2)` 16.3 (13.4–20.4) 16.6 (13.4–20.6) 19.5 (14.6–29.9)
Prepubertal (%) 19 (100) 34 (97.1) 21 (36.8)
White Caucasian (%) 19 (100) 33 (91.7) 71 (97.3)
Family history of T1D (%) 5 (26.3) 2 (5.6) 9 (12.2)
Mean duration of polyuria (weeks) 3.7 (1–14) 3.4 (1–16) 4 (0–24)
Mean duration of polydipsia (weeks) 3.7 (1–14) 3.5 (1–16) 3.9 (0–24)
DKA at diagnosis (%) 5 (26) 7 (20) 7 (10)
Mean HbA1c (SD, range) (%) 9.73 (1.16, 7–11.6) 11.35 (1.86, 7.5–14.5) 12.24 (2.31, 7.8–18.5)
Mean blood glucose (SD) (mmol/liter) 31.8 (10.1) 27.1 (10.1) 24.9 (6.8)
doi:10.1371/journal.pone.0064632.t001
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increased stimulated blood glucose levels and daily insulin dose
per kg [18].
This ‘b-cell function’-pattern is associated with a genetic profile
of T2D related genes including multiple risk alleles of the SNPs in
theWFS1 and CDKN2A/2B [25] genes and protective alleles of the
SNP in the TSPAN8/LGR gene [25], together with multiple
numbers of risk alleles of the SNP in the T1D related gene RNLS
[24] and the two SNPs (rs3842753 and rs689) from the insulin
VNTR region. The SNPs from the insulin VNTR region has been
documented to contribute to T1D susceptibility [30] and
preservation of b-cell function [9] supporting the present findings,
whereas the relation of the other genes with the residual b-cell
function is novel. The HLA risk genotypes were not present in the
genetic pattern of the ‘b-cell function’-component, although they
are important determinants of earlier disease onset [31]. HLA
genotypes do, however, not seem to predict residual b-cell function
[2] and, thus, we would not expect a contribution of the HLA
genotypes in the genetic pattern of the ‘b-cell function’-component
model. The ‘b-cell function’-component is estimated between all
three data blocks (biomarkers, baseline characteristic and genetic
background), whereby the genetic fingerprint also associates to the
described pattern of baseline characteristics. From this analysis it is
not possible to conclude whether the genetic background results in
earlier disease onset, and only indirectly predicts a more rapid b-
cell destruction, or if the genes alone reflect a certain profile of b-
cell destruction. However, conventional regression analyses (data
not shown) indicate that the genetic effect is mediated through
younger age at onset, since the predictive C-peptide effect
disappears when adjusting for age. Thus, multiple risk alleles of
SNPs from the WFS1, CDKN2A/2B and RNLS genes may predict
earlier onset of T1D probably due to a more rapid b-cell
destruction following the first b-cell damage. These findings
confirm a recent work by Howson et al [32], where polymophisms
in the RNLS gene were associated with earlier onset of T1D.
‘ZnT8Ab’-component
The second component ‘ZnT8Ab’ describes a pattern of
ZnT8Abs, which is negatively associated with glucagon levels.
The positive association between the different ZnT8Abs is
described earlier [6,8], whereas the association between ZnT8Abs
and glucagon is novel. A significantly positive association between
ZnT8Arg and stimulated C-peptide 3, 6 and 12 months after
diagnosis has previously been found in the present cohort [8],
being in accordance with other studies [6,7]. The association
pattern between stimulated C-peptide and the baseline character-
istics is, however, much stronger, which is why C-peptide is not
present in the ‘ZnT8Ab’-component. The association between
ZnT8Abs and glucagon indirectly supports the association
between ZnT8Arg and stimulated C-peptide and the intra-islet
hypothesis [33], since high level of stimulated C-peptide combined
with low level of stimulated glucagon may reflect an ongoing
suppressive effect of local insulin directly on the a-cell [34]. Indeed
the b-cell function declines approximately 50% from 1 to 12
months after diagnosis, while the a-cell function increase by 17%
during the same period of time [34]. Furthermore, b-cell derived
zinc has been shown to exert an inhibitory effect on glucagon
secretion although controversy still exists [35]. As free zinc level is
higher in ZnT8 over-expressing cells [36], high levels of ZnT8Abs
may reflect a higher level of zinc in the islets. Thus, the findings in
the present study support the hypothesis that glucagon secretion is
sensitive to suppression by b-cell derived zinc in a complex
interplay with other factors, although the exact role of ZnT8 in a-
cells and also the ZnT8Abs remains uncertain.
The ‘ZnT8Ab’-component was associated with a genetic
fingerprint based on SNPs closest to TAF5L, HNF1B, CDKAL1
and ERBB3 genes, which are all expressed in b-cells (www.
t1dbase.org). No studies have found this combined genetic
association with ZnT8Abs [37], but there are studies relating
TAF5L [38] and ERBB3 [39] to T1D and CDKAL1 [40] and
HNF1B [41] to T2D. We did not find the SLC30A8 gene to be
present in the genetic pattern of the ‘ZnT8Ab’-component,
Figure 2. The course of stimulated C-peptide (pmol/L), HbA1c
(%) and IDAA1c for each child during the 12 months follow-up
colored according to age. A. Raw values of stimulated C-peptide
(pmol/L). Stimulated C-peptide was lowest in the youngest age groups.
B. Raw values of HbA1c (%). The HbA1c level in the very young age
group was lower at onset compared with the older age groups. C. Raw
values of IDAA1c. The children with points below the black are in partial
remission at that time point defined as IDAA1c #9. Very few of the very
young children were in partial remission during the 12 months follow
up (21.1% after 3 months).
doi:10.1371/journal.pone.0064632.g002
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Table 2. Stimulated C-peptide (pmol/L), HbA1c (%) and IDAA1c during 12 months follow up.
1 month 3 mths 6 mths 9 mths 12 mths
Median C-peptide
(range) (pmol/L)
628 (10–1934) 594 (10–1982) 490 (10–1797) – 285.5 (10–2205)
Mean HbA1c (SD) (%) 9.3 (61.2) 7.0 (60.86) 7.3 (61.2) 7.5 (61.2) 7.7 (61.32)
Mean IDAA1c (SD) 11.0 (61.7) 8.7 (61.4) 9.5 (61.9) 10.3 (61.9) 10.7 (62.0)
doi:10.1371/journal.pone.0064632.t002
Figure 3. Multi-block analyses: A. ‘b-cell function’-component: (I) Pattern of the paraclinical biomarkers forming the ‘b-cell function’-
component and the progression of this biomarker pattern during the first 12 months after diagnosis. (II) The pattern of baseline (the time of
diagnosis) characteristics predictive for the biomarker pattern of the ‘b-cell function’-component over time (p = 0.001), were long duration of
symptoms, younger age and DKA and consequently high blood glucose and low level of standard bicarbonate. (III) The pattern of type 1- and T2D
associated SNPs associated with the biomarker pattern of the ‘b-cell function’-component over time (I) (p = 0.006) and the pattern of baseline
characteristics in (II). The best genetic predictors for the biomarker pattern of the ‘b-cell function’-component over time were a combination of more
risk alleles of the INS (rs689 and rs3842753), RNLS (rs10509540), WFS1 (rs10010131) and CDKN2A/2B (rs564398) variants; and less risk alleles of the
TSPAN8-LGR5 (rs7961581) variant. B. ‘ZnT8’-component: (I) Pattern of biomarkers forming the ‘ZnT8-component’ and the progression of this
biomarker pattern during the first 12 months after diagnosis. (II) This component was not significantly associated with baseline characteristics. (III)
The pattern of T1D and T2D associated SNPs associated with the biomarker pattern of the ‘ZnT8’-component over time (I) (p = 0.0005). The best
genetic predictors for the biomarker pattern of the ‘ZnT8Ab’-component were a combination of more risk alleles of the IFIH1 (rs1990760), TAF5L
(rs3753886), HNF1B (TCF2, rs4430796), IL2RA (rs11594656), PTPN2 (rs1893217) and CDKAL1 (rs10946398) variants; and less risk alleles of the ERBB3
(rs2292239) variant.
doi:10.1371/journal.pone.0064632.g003
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although we know there is a very strong correlation between the
rs1326634 SNP of the SLC30A8 gene and the subtype of ZnT8Ab,
such that the CC genotype carriers have higher ZnT8Arg and vice
versa [6,8]. Since the ‘ZnT8Ab’-component describes a pattern of
increasing levels of both the ZnT8Arg and ZnT8Trp autoantibod-
ies, we would not expect to find an effect of the SLC30A8 gene.
Validation
As the statistically methods in the present study are novel the
work is validated both by internal (permutation testing), simulated
external (split half analysis), and true external (reproducibility in
Hvidoere) validation. Internal validation is by far the most used
validation method where a central statistics is tested based on the
data from which it is estimated (e.g. the p-values for a correlation
coefficient). A slightly more rigorous form is the use of a simulated
external validation, where central statistic is estimated in a part of
data, say 80%, and then tested in the remaining part (20%) and
the most rigorous procedure is to try to reproduce the results in
new independent data. The internal approach reveals pattern to
pattern significant association for all components. The split half
analysis further verifies that the biomarker profiles in relation to
the ‘b-cell function’-component and ‘ZnT8Ab’-component, were
consistent, whereas the selection of genes in the split-half
procedure were to some extend inconsistent. However, the split-
half procedure was especially hampered by the loss of modelling
power by reducing the data by 50%. The external validation by
comparison with a model based on an independent dataset (the
Hvidoere Cohort) revealed, that the first component (‘b-cell
function’) is consistent, whereas the pattern of the second
component (‘ZnT8Ab’) was not strong enough to be revealed by
a two component model based on the Hvidoere Cohort. However,
only the ZnT8Trp and the ZnT8Arg are available in the Hvidoere
Cohort, for which reason we cannot expect this component to be
revealed in this cohort.
In conclusion, complex Latent Factor Modelling based on data
from a clinically well characterized Danish cohort of children and
adolescents with newly diagnosed T1D can describe disease
progression patterns and identify biomarker-genetic interacting
partners in complex data. Thus, the present study proposes a novel
method for linking patterns of genetic risk loci with clinical
phenotypes. The study also supports novel hypothesis linking some
of the low-risk genes to earlier onset of T1D and indirectly to more
aggressive b-cell destruction after the first autoimmune insult.
Furthermore, these findings indicate association patterns for
disease progression and generate new hypotheses, which need to
be confirmed in other cohorts or tested in in vitro assays using cell
culture systems. The unravelling and understanding of the natural
history of T1D during the remission phase is crucial as a significant
number of patients still retain a considerable residual b-cell mass at
this time point and might therefore benefit from immunomodu-
latory intervention therapy enhancing b-cell survival and regen-
eration.
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